nach oben

Clinical Oral Investigations

Erschienen in:

01.02.2012 | Original Article

The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes—in vitro study

verfasst von: Andreas M. Pabst, Thomas Ziebart, Felix P. Koch, Katherine Y. Taylor, Bilal Al-Nawas, Christian Walter

Erschienen in: Clinical Oral Investigations | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ) is one of the most often seen side effects in patients treated with bisphosphonates, presenting clinically as a non-healing wound. One theory of BP-ONJ etiology describes a negative effect on soft tissues, especially on keratinocytes, which play an important role in oral wound healing and oral soft tissue regeneration. A high cell viability of keratinocytes, which can migrate to the affected location, is essential for wound healing. The aim of this in vitro study was to investigate the effect of differently potent bisphosphonates on human oral keratinocytes (HOK).

Three nitrogen-containing bisphosphonates (ibandronate, pamidronate, and zoledronate) and one non-nitrogen-containing bisphosphonate (clodronate) were compared concerning their potency on cell viability (calcein assay and MTT assay), migration ability (Boyden chamber migration assay and scratch wound proliferation assay), and apoptosis (TUNEL assay) of HOK.

The nitrogen-containing bisphosphonates, particulary highly potent pamidronate and zoledronate preparations, had a strong negative influence on cell viability, migration ability, and apoptosis of HOK. The non-nitrogen-containing clodronate even increased cell viability in higher concentrations.

This study demonstrates that bisphosphonates have a strong influence on HOK on different cellular levels like cell viability, migration ability, and apoptosis rate. The results support the theory that BP-ONJ is a multifactorially caused disease.

Furthermore, this in vitro study confirms the theory that perioperative interruption of bisphosphonate application during dental surgical procedures might be feasible to promote better tissue regeneration and wound healing.

Diel IJ, Bergner R, Grötz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5:475–482PubMed

Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117PubMedCrossRef

Walter C, Grötz KA, Kunkel M, Al-Nawas B (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15:197–202PubMedCrossRef

Ruggiero SL, Dodson TB, Asseal LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67:2–12PubMed

Allan MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67:61–70CrossRef

Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2009) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14:35–41PubMedCrossRef

Walter C, Pabst A, Ziebart T, Klein MO, Al-Nawas B (2010) Bisphosphonates influence migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis (in press)

Henry D, von Moos R, Vadhan-Raj S, Hunfria V, Spencer A, Hirsh V, Wang J, Jun S, Dansey R, Yeh H (2009) A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Presented at the Joint ECCO 15–34th ESMO Multidisciplinary Congress, Berlin, 20–24 Sept 2009

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M,Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (in press)

10.

Neville-Webbe HL, Coleman RE (2010) Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone diseases. Eur J Cancer 46(7):1211–1222PubMedCrossRef

11.

Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 48:221–223PubMedCrossRef

12.

Santini D, Vincenzi B, Avvisati G et al (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080–1084PubMed

13.

Ziebart T, Pabst A, Klein MO, Kammerer P, Gauss L, Brullamnn D, Al-Nawas B, Walter C (2009) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig (in press)

14.

Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft-tissue toxicity? Bone 41:318–320PubMedCrossRef

15.

Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54:1066–1107PubMedCrossRef

16.

Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228–1236PubMedCrossRef

17.

Moreira MS, Katamaya E, Bombana AC, Marques MM (2005) Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue. A pilot study. Dent Traumatol 21:329–335PubMedCrossRef

18.

Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF (2009) Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144:667–676PubMedCrossRef

19.

Scheper M, Chaisuparat R, Cullen K, Meiller T (2010) A novel-soft tissue in vitro model for bisphosphonate-associated osteonecrosis. Fibrogenesis Tissue Repair 3:6PubMedCrossRef

20.

Felix R, Guenther HL, Fleisch H (1984) The subcellular distribution of [14 C]dichloromethylenebisphosphonate and [14 C]1–hydroxyethylidene-1, 1- bisphosphonate in cultured calvaria cells. Calcif Tissue Int 36:108–113PubMedCrossRef

21.

Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC (1990) Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456–461PubMedCrossRef

22.

Fromigue O, Body JJ (2002) Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Investig 25:539–546

23.

Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD (2009) Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 37:407–416PubMed

24.

Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839–847PubMedCrossRef

25.

Reszka AA, Halasy-Nagy J, Rodan GA (2001) Nitrogen bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59:193–202PubMed

26.

Twiss IM, de Water R, den Hartigh J, Sparidans R, Ramp-Koopmanschap W, Brill H, Wijdeveld M, Vermeij P (1994) Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci 83:699–703PubMedCrossRef

27.

De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–1021PubMedCrossRef

28.

Gonzalez-Moles MA, Bagan-Sebastian JV (2000) Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 29:514–518PubMedCrossRef

29.

Rubegni P, Fimiani M (2006) Images in clinical medicine. Bisphosphonate-associated contact stomatitis. N Engl J Med 355:e25PubMedCrossRef

30.

Walker K, Olson MF (2005) Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 15:62–68PubMedCrossRef

31.

Suri S, Monkkonen J, Taskinen M, Peseson J, Blank MA, Phipps RJ, Rogers MJ (2001) Nitrogen-containing bisphosphoantes induce apoptosis of Caco-2 cells in vitro by inhibition the mevalonate pathway: a model of bisphosphoante-induced gastrointestinal toxicity. Bone 29:336–343PubMedCrossRef

32.

Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534PubMedCrossRef

33.

Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410PubMedCrossRef

34.

Montazeri AH, Erskine JG, McQuaker IG (2007) Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 79:69–71PubMedCrossRef

Titel: The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes—in vitro study
verfasst von: Andreas M. Pabst
Thomas Ziebart
Felix P. Koch
Katherine Y. Taylor
Bilal Al-Nawas
Christian Walter
Publikationsdatum: 01.02.2012
Verlag: Springer-Verlag
Erschienen in: Clinical Oral Investigations / Ausgabe 1/2012
Print ISSN: 1432-6981
Elektronische ISSN: 1436-3771
DOI: https://doi.org/10.1007/s00784-010-0507-6

Neu im Fachgebiet Zahnmedizin

19.04.2024 | Vorhofflimmern | Nachrichten

Newsletter bestellen

Springer Medizin

The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes—in vitro study

Abstract

Neu im Fachgebiet Zahnmedizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

Newsletter

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Nanohybrid and microfilled hybrid versus conventional hybrid composite restorations: 5-year clinical wear performance

Clinical performance of a nanofilled resin composite with and without an intermediary layer of flowable composite: a 2-year evaluation

Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro

In vivo assessment of DNA damage induced in oral mucosa cells by fixed and removable metal prosthodontic appliances

Test–retest reliability of MRI-based disk position diagnosis of the temporomandibular joint

A comparative evaluation of gutta-percha filled areas in curved root canals obturated with different techniques

Neu im Fachgebiet Zahnmedizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

Newsletter